Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke (MINOS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00630396
: March 7, 2008
Results First Posted
: January 13, 2012
Last Update Posted
: January 13, 2012
David Hess, MD
National Institute of Neurological Disorders and Stroke (NINDS)
University of Kentucky
Oregon Health and Science University
Information provided by (Responsible Party):
David Hess, MD, Georgia Health Sciences University
The primary aim of this study is to find out which of 4 different doses of minocycline are safe and well tolerated so that we will know the optimal dose to test in future patients.
Condition or disease
Phase 1Phase 2
Minocycline is a widely used antibiotic and is approved by the Food and Drug Administration (FDA) for treatment of infections and acne. However, doctors do not know whether minocycline will work in stroke patients. Its use in stroke patients is experimental. There is a lot of information from experimental stroke studies in animals that minocycline lessens the damage from a stroke and the animals recover better. Since minocycline is generally a very safe drug in humans and does not have a lot of side effects, investigators at Georgia Health Sciences University (formerly the Medical College of Georgia) believe that it might be a safe and effective drug to improve the outcome in patients with stroke.
Maximally Tolerated Dose of IV Minocycline [ Time Frame: 3 days ]
Investigators closely monitored each subject for evidence of minocycline intolerance. All adverse events were immediately reported for a decision whether to discontinue the study medication and/or reduce the dose. A computer program was used to determine the maximum tolerated dose. After entering information regarding doses and expected toxicities, results for each subject as they were collected were entered. The computer program informed as to (de)escalation, or maintenance of the same dose in the subsequent cohort of enrolled patients.
Secondary Outcome Measures
Half-life of IV Minocycline [ Time Frame: For each subject blood samples were drawn before dose #1 and one hour after starting dose #1. Additional blood was drawn 1, 6, 12, 24, 48, and 72 hours after starting dose #6, which lasted approximately 6 days. ]
In eligible patients enrolled at Georgia Health Sciences University, blood samples were drawn for quantification of minocycline serum concentrations. This enabled the study team to determine the half life of the study drug.
90 Day Modified Rankin Scale Score [ Time Frame: 3 months ]
The modified Rankin Scale (mRS) was performed in person at the 90 day clinic follow-up appointment. The modified Rankin Scale is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6. 0 represents no symptoms. 1 represents no significant disability. 2 represents slight disability. 3 represents moderate disability. 4 represents moderately severe disability. 5 represents severe disability. 6 represents death.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
19 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
over 18 years of age
acute onset focal neurologic deficit consistent with acute ischemic stroke, or computed tomographic scan consistent with acute cerebral ischemia
onset of symptoms less than 6 hours
measurable neurologic deficit (National Institutes of Health [NIH] Stroke Scale >/= 1)
allergy to tetracycline antibiotics
women of child-bearing potential
known hepatic and/or renal insufficiency
history of intolerance to minocycline
dizziness at the time of stroke or in the past month (by self-report)
aphasia likely to interfere with patients ability to report adverse effects
previous functional disability
stuporous or comatose
presence of another serious illness likely to confound the study
unlikely to be available for 90 day follow-up
severe stroke (National Institutes of Health [NIH] Stroke Scale >22)
undergoing an interventional neuro-radiological intervention in first 12 hour